InvestorsHub Logo
Followers 139
Posts 5289
Boards Moderated 0
Alias Born 03/01/2013

Re: None

Tuesday, 12/16/2014 12:19:10 PM

Tuesday, December 16, 2014 12:19:10 PM

Post# of 10489
Kanak Kanti Galena: I Am Bullish, Nobody Has Paid Me For My Stance
Dec. 9, 2014 8:32 AM ET
| About: Galena Biopharma, Inc. (GALE)

Disclosure: The author has no positions in any stocks mentioned, but may initiate a long position in GALE over the next 72 hours. (More...)
Summary

Galena has radically changed its management.
Its portfolio is quite decent despite the paid hype and ensuing fallout.
The scandal has devalued the stock, and possibly undervalued it.

At the height of the Galena (NASDAQ:GALE) scandal, SA author MTF Investing predicted that a few catalysts may cause Galena's price to move. Of these, one has come to pass, and another is about to happen.

In the last 12 months, almost half of Galena's management has been replaced with new faces, with people that are old hands in the industry. The company got itself a new General Counsel, a registered patent attorney with impeccable creds as a past President of the Orange County Patent Law Association, among her other impressive achievements. There are 2 new sober-looking VPs, one senior, one junior, both professionally accomplished, in the Clinical Sciences and Operations department, and since August 22, incidentally the day after another death-dealing Richard Pearson article here on Seeking Alpha, the company got itself a new CEO. Mark W. Schwartz, Ph.D, replaced Mark J. Ahn, Ph.D, at the helm of Galena's affairs. Affairs that, one would hope, would not involve illegal collusions with disreputable stock-promoting outfits like the Dream Team Group.

That, precisely, seems to be the idea behind the major changes in the management of the company, including the decisive "no severance or other compensation is payable to Dr. Ahn" statement included in the related 8-K. I am not sure how irregular this was, or whether this was just usual business. To my mind, however, this told me that the company was trying to distance itself from its notorious past, and that too quite pointedly. That was catalyst number one, a drastic management change.

The other catalyst was to be information about the NeuVax trial, and according to a new press release, that too is about to happen. These days, any Galena PR is looked at like something the cat brought in, but this is a press release about an upcoming press release, so to say.

http://seekingalpha.com/article/2741865-galena-i-am-bullish-however-nobody-has-paid-me-for-my-stance


You've been listening to too much AF, the Richard Pearson mentioned here and other assorted scum-de-la-scum of the pseudo-science-reporting world, and old and twisted reports.
You are right that biotechs are fragile b/c they're so dependent on financing and risky science, high risk but also potentially high reward and anyway, the people who work there have more human worth in their pinky fingers than any of these clowns writing to take them down. JIMHO

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.